ArticleHeliyon2024
Diagnostic performance of EfficientNetV2-S method for staging liver fibrosis based on multiparametric MRI.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MidFusionEfficientV2: Improving Ophthalmic Diagnosis with Mid-Level RGB-LBP Fusion and SE Attention.Journal of clinical medicine · 2026Article
- Interpreting Venous and Arterial Ulcer Images Through the Grad-CAM Lens: Insights and Implications in CNN-Based Wound Image Classification.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Problem: Previous studies had confirmed that some deep learning models had high diagnostic performance in staging liver fibrosis. However, training efficiency of models predicting liver fibrosis need to be improved to achieve rapid diagnosis and precision medicine. Aim: The deep learning framework of EfficientNetV2-S was noted because of its faster training speed and better parameter efficiency compared with other models. Our study sought to develop noninvasive predictive models based on EfficientNetV2-S framework for staging liver fibrosis. Methods: Patients with chronic liver disease who underwent multi-parametric abdominal MRI were included in the retrospective study. Data augmentation methods including horizontal flip, vertical flip, perspective transformation and edge enhancement were applied to multi-parametric MR images to solve the data imbalance between different liver fibrosis groups. The EfficientNetV2-S models were used for the prediction of liver fibrosis stages F1-2, F1-3, F3, F4 and F3-4. We evaluated the diagnostic performance of our models in training, validation, and test sets by using receiver operating characteristic curve (ROC) analysis. Results: The total training time of EfficientNetV2-S was about 6 h. For differentiating of F1-2 vs F3, the accuracy, sensitivity and specificity of EfficientNetV2-S model were 96.2 %, 96.4 % and 96.0 % in the test set. The AUC in test set was 0.559. The accuracy, sensitivity and specificity were 82.1 %, 74.5 % and 89.6 % in the test set by using EfficientNetV2-S model to differentiate F1-2 vs F3-4, and the AUC in test set were 0.763. For differentiating F1-3 vs F4, the accuracy, sensitivity and specificity of EfficientNetV2-S model were 71.5 %, 73.4 % and 69.5 % in the test set. The AUC was 0.553 in test set. For differentiating F1-2 vs F4, the accuracy, sensitivity and specificity of our model were 84.3 %, 80.2 % and 88.3 % in the test set, and the AUC was 0.715, respectively. For differentiating F3 vs F4, the accuracy, sensitivity and specificity of EfficientNetV2-S model were 92.5 %, 89.1 % and 95.6 % in the test set, and the AUC was 0.696 in the test set. Conclusions: The EfficientNetV2-S models based on multi-parametric MRI had the feasibility for staging of liver fibrosis because they showed high training speed and diagnostic performance in our study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.